BTNX Inc. (BTNX) is pleased to share an update on its ongoing partnership with Ireland-based distributor One-Use Diagnostics (One-Use), which distributes our harm reduction and drug testing products across Europe. Together, we are working to expand access to these essential tools throughout the European market.
Through this partnership, BTNX combines its experience developing drug checking solutions with One-Use’s knowledge of the European harm reduction landscape. Together, the organizations are working to make practical, reliable drug checking tools more accessible while responding to the unique needs of communities and harm reduction organizations throughout the region.
“Working with One-Use has not only allowed us to expand access to these vital drug checking tools across Europe but has also given us valuable insight into the unique requirements of the region. That understanding allows us to continually adapt our product offerings and better support the organizations and communities that rely on them.”
- Iqbal Sunderani, CEO, BTNX Inc.
One-Use was founded in 2015 with a clear purpose: to strengthen harm reduction efforts through the provision of practical, evidence-based solutions that support the well-being and health of people who use drugs
As the drug landscape has continued to evolve, so too has One-Use's commitment to innovation and supporting further harm reduction initiatives. Recognising the increasing importance of drug checking and substance monitoring for overdose prevention, One-Use has expanded into diagnostic testing through partnership with BTNX, a global leader in rapid diagnostic technologies.
United by a shared commitment to public health and evidence-based practices for harm reduction, our partnership with BTNX enables organisations to access reliable testing solutions that support informed decision-making and strengthen the responses of frontline services.
Together, BTNX and One-Use are committed to advancing access to harm reduction diagnostics internationally, to improve the health and wellbeing of people who use drugs.
“Partnering with BTNX reflects our shared commitment to advancing harm reduction solutions through innovation. Together, we are working to expand access internationally to evidence-based products that support frontline workers in improving the well-being of communities and people that use drugs.”
- Michael Considine, CEO, One-Use Diagnostics
BTNX has a long history of developing and manufacturing accessible, effective rapid testing solutions, including drug checking test strips used by public health organizations, harm reduction programs, researchers and individuals.
BTNX test strips have been evaluated by academic institutions, public health organizations and independent research groups, helping build a growing body of evidence around their use in harm reduction settings. Public health authorities and community organizations across North America have incorporated BTNX test strips into harm reduction initiatives designed to help people make more informed decisions and reduce the risks associated with an increasingly unpredictable drug supply.
Every BTNX harm reduction product is developed with the end user in mind. From collaborating with third-party researchers on product evaluation and validation to continually refining strip design, usability and performance, BTNX is committed to providing drug checking tools that meet the evolving needs of harm reduction programs and the communities they serve.
Through partnership with One-Use Diagnostics, BTNX is bringing this experience to Europe while learning directly from organizations working within the region. The partnership allows both companies to better understand local requirements, emerging drug trends and the needs of European harm reduction programs, helping inform products and solutions designed for the market.
BTNX and One-Use Diagnostics remain committed to expanding access to effective harm reduction tools and supporting evidence-based approaches that help reduce the risks associated with drug use.
Canada